Profiling of Blood Immune Biomarkers in Bladder Cancer


  • Study type

  • Study IDs

  • Describes the nature of a clinical study. Types include:

    • Observational study — observes people and measures outcomes without affecting results.
    • Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
    • Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
  • Site IRB
    • Rochester, Minnesota: 15-005505
    Sponsor Protocol Number: 15-005505

About this study

The purpose of this study is to characterize the immune markers of granulocytes, lymphocytes and monocytes in peripheral blood of newly diagnosed bladder cancer patients.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. If you need assistance understanding the eligibility criteria, please contact the study team.

See eligibility criteria

Inclusion Criteria:

  • Male and female 19 to 85 years with urothelial bladder cancer

Exclusion Criteria: 

  • Age 18 and under
  • Pregnant women
  • Mental abnormalities

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

John Cheville, M.D.

Closed for enrollment

Contact information:

John Cheville M.D.



Mayo Clinic Footer